| Business Summary | | HemaSure
Inc.
develops
and
supplies
blood
filtration
technologies
designed
to
help
meet
demand
for
a
safer,
more
reliable
blood
supply.
The
Company's
blood
filtration
technologies
are
designed
to
reduce
virus-carrying
white
blood
cells
(leukocytes)
in
donated
blood
to
nominal
levels,
in
a
process
known
as
leukoreduction.
The
Company
initiated
sales
of
the
r\LS
System
in
the
United
States
in
the
third
quarter
1999.
HemaSure's
r\LS
System
was
designed
for
leukocyte
filtration
by
blood
centers
and
hospital
blood
banks
immediately
prior
to
blood
storage.
The
r\LS
System
is
based
on
a
proprietary
filter
medium
comprised
of
multiple
fibrous
components.
In
March
2001,
the
Company
signed
a
termination
and
release
agreement
with
Gambro
Inc.,
effective
November
2000,
which
ended
their
distribution
and
development
agreement.
On
February
3,
2001,
the
Company
agreed
to
sell
substantially
all
of
its
non-cash
assets
to
Whatman
Bioscience
Inc.,
a
Massachusetts
corporation. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | HMSR
develops
and
delivers
innovative
filtration
technologies
designed
to
set
standards
of
safety
for
processing
blood
components
worldwide.
For
the
three
months
ended
3/31/01,
decreased
99%
to
$12
thousand.
Net
loss
increased
27%
to
$4.2
million.
Revenues
reflect
the
termination
of
the
supply
agreement
with
ARC
in
9/00,
and
subsequently
the
distribution
agreement
with
Gambro
in
11/00.
Higher
losses
reflect
higher
consulting
and
advisory
costs. | More
from
Market Guide: Significant
Developments |
| | | | FY1999 Pay | |
| Timothy Barberich, 51 Chairman | -- | John McGuire, 53 Pres,
CEO, Director | $399K | James Murphy, 43 Sr.
VP, Fin. and Admin., Treasurer and Sec. | 177K | Peter Sutcliffe, 50 VP
and COO | 187K | Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|